公开(公告)号：EP4172155A1

公开(公告)日：2023-05-03

申请号：EP21752782.9

申请日：2021-06-25

申请人： Lightwave Logic, Inc.

发明人： PECINOVSKY, Cory ,  JOHNSON, Barry ,  RAMANN, Ginelle

IPC分类号： C07D405/08 ,  C09B23/01 ,  C09B1/00 ,  G02F1/00 ,  G02F1/065 ,  G02F1/15

公开(公告)号：EP3390395A1

公开(公告)日：2018-10-24

申请号：EP16816363.2

申请日：2016-12-16

申请人： Loxo Oncology Inc.

发明人： GUISOT, Nicolas

IPC分类号： C07D405/14 ,  A61K31/415 ,  A61K31/4155 ,  C07D231/14 ,  C07D401/04 ,  C07D401/06 ,  C07D403/04 ,  C07D405/04 ,  C07D405/06 ,  C07D405/08 ,  C07D413/06 ,  A61P35/00

摘要： This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

公开(公告)号：EP2427444B1

公开(公告)日：2015-12-16

申请号：EP10716982.3

申请日：2010-04-29

申请人： Merck Sharp & Dohme Corp.

发明人： PASTERNAK, Alexander ,  SHAHRIPOUR, Aurash ,  TANG, Haifeng ,  TEUMELSAN, Nardos, H. ,  YANG, Lihu ,  ZHU, Yuping ,  WALSH, Shawn, P.

IPC分类号： C07D307/88 ,  C07D405/08 ,  C07D407/08 ,  C07D413/08 ,  C07D487/08 ,  C07D493/04 ,  C07D295/135 ,  C07D295/155 ,  A61K31/495 ,  A61K31/529 ,  A61P7/10

CPC分类号： C07D307/88 ,  C07D295/135 ,  C07D295/155 ,  C07D405/08 ,  C07D407/08 ,  C07D413/08 ,  C07D487/08 ,  C07D493/04

公开(公告)号：EP2771322A2

公开(公告)日：2014-09-03

申请号：EP12787235.6

申请日：2012-10-23

申请人： AbbVie Inc.

发明人： BAYBURT, Erol K. ,  CLAPHAM, Bruce ,  COX, Phil B. ,  DAANEN, Jerome F. ,  GOMTSYAN, Arthur ,  KORT, Michael E. ,  KYM, Philip R. ,  VOIGHT, Eric A. ,  SCHMIDT, Robert G. ,  DART, Michael J. ,  GFESSER, Gregory

IPC分类号： C07D213/30 ,  C07D239/26 ,  C07D405/06 ,  C07D405/08 ,  C07D401/06 ,  A61K31/352 ,  A61K31/4402 ,  A61K31/4433 ,  A61K31/505 ,  C07D311/04 ,  A61P25/00 ,  A61P29/00

CPC分类号： C07D213/38 ,  A61K31/192 ,  A61K31/435 ,  A61K31/4418 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/505 ,  A61K45/06 ,  C07D213/30 ,  C07D213/34 ,  C07D213/72 ,  C07D215/14 ,  C07D221/04 ,  C07D239/26 ,  C07D311/04 ,  C07D401/06 ,  C07D405/06 ,  C07D405/08 ,  C07D405/10 ,  C07D417/08 ,  A61K2300/00

摘要： Disclosed herein are modulators of TRPV3 of Formula (I) (I) wherein p is 1, 2, 3, or 4, and G
1 , X
1 , X
2 , X
3 , X
4 , X
5 , G
2 , Z
1 , R
a , R
b , and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

公开(公告)号：EP2685828A4

公开(公告)日：2014-08-13

申请号：EP12757995

申请日：2012-03-14

申请人： MERCK SHARP & DOHME

发明人： NAIR ANILKUMAR G ,  DUCA JOSE S ,  DWYER MICHAEL P ,  KOZLOWSKI JOSEPH A ,  ROSENBLUM STUART B

IPC分类号： A01N43/64 ,  A61K31/41 ,  C07D209/52 ,  C07D401/08 ,  C07D403/06 ,  C07D403/08 ,  C07D405/04 ,  C07D405/08 ,  C07D409/08 ,  C07D413/04 ,  C07D417/04 ,  C07D417/08 ,  C07D471/04 ,  C07D493/14

CPC分类号： C07D209/52 ,  C07D401/06 ,  C07D401/08 ,  C07D401/14 ,  C07D403/06 ,  C07D403/08 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D405/08 ,  C07D409/04 ,  C07D409/08 ,  C07D409/14 ,  C07D413/04 ,  C07D417/08 ,  C07D471/04

公开(公告)号：EP2660241A2

公开(公告)日：2013-11-06

申请号：EP13179069.3

申请日：2011-12-16

申请人： BioMarin Pharmaceutical Inc.

发明人： Chu, Daniel ,  Wang, Bing ,  Ye, Tao

IPC分类号： C07D401/08 ,  C07D403/08 ,  C07D405/08 ,  C07D413/08 ,  C07D471/04 ,  C07J43/00 ,  C07J61/00 ,  C07J63/00 ,  C07J73/00 ,  A61P5/26 ,  A61P5/42 ,  A61P5/46 ,  A61P35/00 ,  A61K31/56

CPC分类号： C07J73/008 ,  C07D401/08 ,  C07D403/08 ,  C07D405/08 ,  C07D413/08 ,  C07D471/04 ,  C07J1/0011 ,  C07J13/005 ,  C07J21/005 ,  C07J31/006 ,  C07J43/003 ,  C07J61/00 ,  C07J63/002 ,  C07J73/003 ,  C07J73/005

摘要： Provided herein are inhibitors of CYP11B, CYP17, and/or CYP21 enzymes of Formula Z, IX, X, XI, XII, XIII, XIV, XV, XVI, or XVII. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions.

摘要翻译： 本文提供了式Z，IX，X，XI，XII，XIII，XIV，XV，XVI或XVII的CYP11B，CYP17和/或CYP21酶的抑制剂。 本文还描述了包含本文所述的至少一种化合物和本文所述的化合物或药物组合物用于治疗雄激素依赖性疾病，病症和病症的药物组合物。

公开(公告)号：EP2142538B1

公开(公告)日：2011-10-26

申请号：EP08714240.2

申请日：2008-02-11

申请人： Schering Corporation

发明人： ZHENG, Junying ,  MCCORMICK, Kevin, D. ,  CHAO, Jianhua ,  BOYCE, Christopher, W. ,  ASLANIAN, Robert, G. ,  YU, Younong

IPC分类号： C07D405/06 ,  C07D405/08 ,  C07D405/14 ,  C07D409/06 ,  C07D417/14 ,  C07D491/052 ,  A61K31/353 ,  A61P25/06

CPC分类号： C07D405/06 ,  C07D405/08 ,  C07D405/14 ,  C07D409/06 ,  C07D417/14 ,  C07D491/052

摘要： In its many embodiments, the present invention provides a novel class of chroman compounds of formula I as α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of prepaxing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.

公开(公告)号：EP1751144B1

公开(公告)日：2008-08-27

申请号：EP05755642.5

申请日：2005-05-25

申请人： Schering Corporation

发明人： CHELLIAH, Mariappan, V. ,  CHACKALAMANNIL, Samuel ,  XIA, Yan ,  CLASBY, Martin, C. ,  GREENLEE, William, J. ,  WANG, Yuguang ,  VELTRI, Enrico, P. ,  WU, Wenxue ,  GRAZIANO, Michael, P. ,  KOSOGLOU, Teddy ,  CHINTALA, Madhu

IPC分类号： C07D405/08 ,  C07D493/04 ,  A61K31/443 ,  A61K31/4433 ,  A61P9/00 ,  A61P25/28 ,  A61P11/00

CPC分类号： C07D493/04 ,  C07D405/06

摘要： A compound represented by the structural formula (Chemical formula should be inserted here as it appears on abstract in paper form) and pharmaceutically acceptable salts and solvents thereof is disclosed, wherein: the single-dashed line between the ring carbons to which R10 and R34 are attached represents either a single bond or a double bond; the double-dashed line between X and the carbon to which Y is attached represents either a single bond or an absent bond; X is -O- or -NR6- when the double-dashed line represents a single bond; X is H, -OH or -NHR20 when the double-dashed line represents an absent bond; and other parameters are as defined herein. Also disclosed are pharmaceutical compositions and combinations containing said compounds and their uses as thrombin receptor antagonists and binders to cannabinoid receptors.

公开(公告)号：EP1751144A1

公开(公告)日：2007-02-14

申请号：EP05755642.5

申请日：2005-05-25

申请人： SCHERING CORPORATION

发明人： CHELLIAH, Mariappan, V. ,  CHACKALAMANNIL, Samuel ,  XIA, Yan ,  CLASBY, Martin, C. ,  GREENLEE, William, J. ,  WANG, Yuguang ,  VELTRI, Enrico, P. ,  WU, Wenxue ,  GRAZIANO, Michael, P. ,  KOSOGLOU, Teddy ,  CHINTALA, Madhu

IPC分类号： C07D405/08 ,  C07D493/04 ,  A61K31/443 ,  A61K31/4433 ,  A61P9/00 ,  A61P25/28 ,  A61P11/00

CPC分类号： C07D493/04 ,  C07D405/06

摘要： A compound represented by the structural formula (Chemical formula should be inserted here as it appears on abstract in paper form) and pharmaceutically acceptable salts and solvents thereof is disclosed, wherein: the single-dashed line between the ring carbons to which R10 and R34 are attached represents either a single bond or a double bond; the double-dashed line between X and the carbon to which Y is attached represents either a single bond or an absent bond; X is -O- or -NR6- when the double-dashed line represents a single bond; X is H, -OH or -NHR20 when the double-dashed line represents an absent bond; and other parameters are as defined herein. Also disclosed are pharmaceutical compositions and combinations containing said compounds and their uses as thrombin receptor antagonists and binders to cannabinoid receptors.

摘要翻译： 公开了由结构式（化学式应当插入本文作为摘要以纸形式出现）的化合物及其药学上可接受的盐和溶剂，其中：R10和R34所代表的环碳之间的单点划线 连接表示单键或双键; X与Y所连接的碳之间的双点划线表示单键或无键; 当双虚线表示单键时，X是-O-或-NR6-; 当双虚线表示无键时，X是H，-OH或-NHR20; 和其他参数如本文所定义。 还公开了含有所述化合物及其作为凝血酶受体拮抗剂和大麻素受体结合剂的用途的药物组合物和组合。

公开(公告)号：EP1414813B1

公开(公告)日：2006-09-13

申请号：EP02763208.2

申请日：2002-06-21

申请人： Medicines for Malaria Venture

发明人： VENNERSTROM, J., University of Nebraska Med. Ctr. ,  CHOLLET, Jacques, Pharma Research Department ,  DONG, Y., University of Nebraska Medical Center ,  MATILE, Hugues, Pharma Research Department ,  PADMANILAYAM, M., University of Nebraska Med. Ctr. ,  TANG, Y., University of Nebraska Medical Center ,  CHARMAN, William N., Victorian College of Pharmacy

IPC分类号： C07D323/02 ,  C07D493/10 ,  C07D405/14 ,  C07D405/08 ,  C07D419/08 ,  C07D521/00 ,  A61P33/06

CPC分类号： C07D405/12 ,  A61K31/335 ,  A61K31/357 ,  C07D323/02 ,  C07D405/14 ,  C07D491/10 ,  C07D493/10 ,  C07D495/10 ,  Y02A50/411 ,  Y02A50/423 ,  A61K2300/00

摘要： A means and method for treating malaria using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl or spiropiperidyl ring on the other side of the trioxolane group, whereby the spirocyclohexyl ring is preferably functionalized or substituted at the 4-position or a spiropiperidyl ring that is functionalized or substituted at the nitrogen atom. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites.